IntechOpen eBooks, Год журнала: 2025, Номер unknown

Опубликована: Март 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent metabolic disorder globally, has presented an urgent need for effective therapeutic agents. The complex pathogenesis of MASLD and the failure numerous clinical trials targeting this have prompted exploration probiotic intervention as novel strategy. Emerging evidence underscores pivotal role gut-liver axis in progression, particularly through dysregulation gut microbiota composition, impaired intestinal barrier integrity, aberrant bacterial metabolite signaling. Preclinical studies indicate that specific strains may ameliorate by restoring microbial homeostasis, fortifying function, attenuating hepatic inflammation via crosstalk. Preliminary further support beneficial effects probiotics reducing steatosis improving parameters. Future research should prioritize elucidating strain-specific mechanisms, optimizing formulations, addressing challenges related to long-term efficacy, safety, personalized regimens. This review comprehensively evaluates current on applications treatment highlights critical directions advancing translational field.

Язык: Английский